Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats

L-3, 4-dihydroxyphenylalanine (L-dopa) is the gold standard for symptomatic treatment of Parkinson's disease (PD), but long-term therapy is associated with the emergence of L-dopa-induced dyskinesia (LID). In the present study, L-dopa and benserazide were loaded by poly (lactic-co-glycolic acid...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Cheng-long, Wang, Wen-Wen, Zhang, Su-fang, Yuan, Ming-Lu, Che, Jun-Yi, Gan, Jing, Song, Lu, Yuan, Wei-En, Liu, Zhen-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267205/
https://www.ncbi.nlm.nih.gov/pubmed/25511986
http://dx.doi.org/10.1038/srep07506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267205/
https://www.ncbi.nlm.nih.gov/pubmed/25511986
http://dx.doi.org/10.1038/srep07506

Ejemplares similares